AU2001296578A1 - Combination therapy for the treatment of estrogen-sensitive disease - Google Patents

Combination therapy for the treatment of estrogen-sensitive disease

Info

Publication number
AU2001296578A1
AU2001296578A1 AU2001296578A AU9657801A AU2001296578A1 AU 2001296578 A1 AU2001296578 A1 AU 2001296578A1 AU 2001296578 A AU2001296578 A AU 2001296578A AU 9657801 A AU9657801 A AU 9657801A AU 2001296578 A1 AU2001296578 A1 AU 2001296578A1
Authority
AU
Australia
Prior art keywords
antiestrogen
drug
inhibitor
enzyme inhibitor
metabolism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001296578A
Other languages
English (en)
Inventor
Peter Langecker
S. Mark Moran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intarcia Therapeutics Inc
Original Assignee
Biomedicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedicines Inc filed Critical Biomedicines Inc
Publication of AU2001296578A1 publication Critical patent/AU2001296578A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2001296578A 2000-10-06 2001-10-03 Combination therapy for the treatment of estrogen-sensitive disease Abandoned AU2001296578A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23877200P 2000-10-06 2000-10-06
US60238772 2000-10-06
PCT/US2001/031060 WO2002030429A1 (en) 2000-10-06 2001-10-03 Combination therapy for the treatment of estrogen-sensitive disease

Publications (1)

Publication Number Publication Date
AU2001296578A1 true AU2001296578A1 (en) 2002-04-22

Family

ID=22899242

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001296578A Abandoned AU2001296578A1 (en) 2000-10-06 2001-10-03 Combination therapy for the treatment of estrogen-sensitive disease

Country Status (14)

Country Link
US (5) US20020119502A1 (hu)
EP (1) EP1330251A4 (hu)
JP (1) JP2004510994A (hu)
CN (1) CN1471400A (hu)
AU (1) AU2001296578A1 (hu)
BR (1) BR0114655A (hu)
CA (1) CA2424299A1 (hu)
HU (1) HUP0301276A2 (hu)
IL (1) IL155237A0 (hu)
MX (1) MXPA03003032A (hu)
NZ (1) NZ525105A (hu)
PL (1) PL361874A1 (hu)
RU (1) RU2003112974A (hu)
WO (1) WO2002030429A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2253319A1 (en) * 2001-05-16 2010-11-24 Novartis AG Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent.
US6967194B1 (en) * 2002-09-18 2005-11-22 Susan Matsuo Bio-identical hormones and method of use
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
EP1623713A1 (en) * 2004-07-09 2006-02-08 Proskelia SAS Cominations of pure anti-estrogen with aromatase inhibitors
WO2011002096A1 (ja) * 2009-07-03 2011-01-06 独立行政法人理化学研究所 Ｐｅｔ用標識化合物
PL2580210T3 (pl) 2010-06-10 2017-09-29 Seragon Pharmaceuticals, Inc. Modulatory receptora estrogenowego i ich zastosowania
BR112014014124A2 (pt) 2011-12-14 2017-08-22 Seragon Pharmaceutical Inc Moduladores do receptor de estrogênio fluorados e usos dos mesmos
WO2017093776A1 (en) * 2015-11-30 2017-06-08 Pharnext Method for adapting doses of combination therapies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
US5064813A (en) * 1984-08-02 1991-11-12 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4760053A (en) * 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US5023234A (en) * 1985-02-08 1991-06-11 Fernand Labrie Combination male breast cancer therapy
US4775660A (en) * 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
EP0462189B1 (en) * 1989-03-10 1995-09-27 Endorecherche Inc. Combination therapy for treatment of estrogen sensitive diseases
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites

Also Published As

Publication number Publication date
RU2003112974A (ru) 2004-11-27
US20020119502A1 (en) 2002-08-29
NZ525105A (en) 2004-10-29
BR0114655A (pt) 2004-02-10
MXPA03003032A (es) 2003-06-06
CN1471400A (zh) 2004-01-28
JP2004510994A (ja) 2004-04-08
US20050176691A1 (en) 2005-08-11
EP1330251A1 (en) 2003-07-30
IL155237A0 (en) 2003-11-23
US20050228053A1 (en) 2005-10-13
US20050232862A1 (en) 2005-10-20
PL361874A1 (en) 2004-10-04
EP1330251A4 (en) 2006-03-15
US20050130945A1 (en) 2005-06-16
CA2424299A1 (en) 2002-04-18
WO2002030429A1 (en) 2002-04-18
HUP0301276A2 (hu) 2003-11-28

Similar Documents

Publication Publication Date Title
JP2959838B2 (ja) エストロゲン感受性疾患の治療のための組合せ療法
AU643445B2 (en) Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US11771682B2 (en) AR+ breast cancer treatment methods
CA1278515C (en) Pharmaceutical composition for combination therapy of hormone dependent cancers
EP0195015B1 (en) Pharmaceutical composition for combination therapy of hormone dependent cancers
US20050228053A1 (en) Combination therapy for the treatment of estrogen-sensitive disease
US6423698B1 (en) Combination therapy for the prophylaxis and/or treatment of benign prostatic hyperplasia
US4775661A (en) Combination therapy for treatment of female breast cancer
CN104244953A (zh) 用于治疗雄激素缺乏的联合治疗
Lundgren Progestins in Breast Cancer Treatment: A Reveiw
Ingle et al. Aromatase inhibitors for therapy of advanced breast cancer
JPWO2004035089A1 (ja) ホルモン依存性癌の治療剤
KR20160101027A (ko) 제약 조합물
Jones et al. Exemestane: a novel aromatase inactivator for breast cancer
CA1278748C (en) Pharmaceutical composition for combination therapy of hormone dependent cancers
Shenton et al. 12 Clinical Utility

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application